SIGANasdaqPharmaceutical PreparationsUS GAAP · USD

SIGA Technologies Inc

SIGA Technologies is a U.S.-based pharmaceutical company focused on developing and commercializing treatments for orthopoxvirus infections, centered on its oral antiviral product TPOXX® (tecovirimat). The company’s business combines drug development, regulatory maintenance, intellectual property management, and third-party manufacturing and distribution arrangements across the United States and international markets.

Kysy yhtiöstä
Liikevaihto94,6milj. USD
−31,8 %v/v
Liikevoitto (EBIT)23,7milj. USD
−66,1 %v/v
EBIT-marginaali25,1%
−25,4 %-yks.v/v
Nettotulos23,3milj. USD
−60,7 %v/v
Vapaa kassavirta43,1milj. USD
−11,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

050100150milj. USD2020: 125 milj. USD2020: EBIT 85 milj. USD20202021: 134 milj. USD2021: EBIT 89 milj. USD20212022: 111 milj. USD2022: EBIT 43 milj. USD20222023: 140 milj. USD2023: EBIT 84 milj. USD20232024: 139 milj. USD2024: EBIT 70 milj. USD20242025: 95 milj. USD2025: EBIT 24 milj. USD20259524
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: SIGA Technologies Inc

Liiketoiminta

Osuus liikevaihdosta
TPOXX® oral antiviral80 %

Commercial sales and supply of oral TPOXX® for orthopoxvirus-related indications and government stockpiles.

Supportive services10 %

Contract-related supportive services tied to product delivery, performance obligations, and customer programs.

International sales and promotion arrangements10 %

Sales and commercialization activity outside the United States through international contract structures.

Tuotteet

Raportoitu · osuus liikevaihdosta
93,1%FY2025100 %
  • Product Sales and Supportive Services93,1 %
  • Research and Development6,9 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

SIGA sells primarily to government customers and public-health procurement channels that buy TPOXX® for biodefense preparedness and outbreak response. It also serves international counterparties and, through promotion agreements, reaches non-U.S. markets where regulatory approvals and procurement pathways differ by country.

U.S. Government / BARDA

Buys oral TPOXX® under government supply contracts for preparedness and response use.

International government and public-health customers

Purchases oral TPOXX® for national stockpiles or outbreak response through country-specific arrangements.

Promotion and distribution counterparties

Commercial partners that market or facilitate sales outside the U.S. under defined territory agreements.

Strategia

SIGA’s strategy centers on maintaining and extending the commercial and regulatory position of TPOXX® while preserving intellectual property protection across major markets. The company also depends on third-party manufacturing and international promotion structures, so execution quality in supply, regulatory compliance, and contract performance is central to its business model.

Defend and expand TPOXX® intellectual propertyKeskipitkä aikaväli

Patent and trademark protection supports exclusivity and commercial durability.

Preserve regulatory access across jurisdictionsKeskipitkä aikaväli

Market access depends on maintaining approvals and meeting local requirements.

Reliably execute outsourced manufacturing and deliveryLyhyt aikaväli

The company depends on CMOs for production, packaging and testing.

Maantiede

Q2/2026

SIGA is headquartered in the United States, where it retains sales and marketing rights for oral TPOXX® and manages core regulatory responsibilities. Outside the U.S., the company relies on international promotion and supply arrangements, with sales activity spanning multiple foreign jurisdictions and one-country deliveries in reported periods.

USA52 %
Other countries (US filing)24 %
Asia Pacific24 %
EMEA0,5 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

SIGA’s business is concentrated in a single product and depends on government procurement, regulatory approvals, and third-party manufacturing execution. Key risks include supply-chain disruption, cyber incidents, patent or approval setbacks, and the possibility that international biodefense demand develops more slowly than expected.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Dependence on U.S. government contracts1Third-party manufacturing and supply-chain disruption2Patent and trademark protection challenges3Regulatory approval risk outside the United States4Cybersecurity and data integrity incidents5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Dependence on U.S. government contractsVaikutus: KorkeaTodennäköisyys: Korkea

    A large share of demand is tied to BARDA and other public-sector procurement.

    Kohdistuu: Revenue timing and contract continuity

  2. Third-party manufacturing and supply-chain disruptionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    SIGA does not own manufacturing infrastructure and relies on CMOs.

    KohdistuuProductionPackagingTestingDelivery schedules
  3. Patent and trademark protection challengesVaikutus: KorkeaTodennäköisyys: Matala

    Exclusivity depends on maintaining broad IP coverage across jurisdictions.

    Kohdistuu: Competitive position and product lifecycle

  4. Regulatory approval risk outside the United StatesVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Foreign commercialization requires country-specific approvals and compliance.

    Kohdistuu: International market access

  5. Cybersecurity and data integrity incidentsVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    A breach could affect clinical, manufacturing or quality records.

    KohdistuuOperationsRegulatory submissionsRecovery costs
Kysy Clarifolta: SIGA Technologies Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition over time

Management identifies this as the most critical accounting estimate.

Vaikutus: Affects timing of revenue, cost of sales and supportive services

Cumulative catch-up adjustments

Changes in estimates are recognized quarterly as facts become known.

Vaikutus: Can create volatility in reported quarterly revenue and margins

International sales timing

Revenue depends on delivery timing and contract counterparty structure.

Vaikutus: Can shift revenue between quarters and between U.S. and foreign markets

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Teva Pharmaceutical Industries Limited

TEVA · Pharmaceutical Preparations

Vir Biotechnology, Inc.

VIR · Biological Products, (No Diagnostic Substances)

OraSure Technologies, Inc

OSUR · Surgical & Medical Instruments & Apparatus

Silexion Therapeutics Corp

SLXN · Biological Products, (No Diagnostic Substances)

Zicix Corp

ZICX · Services-Advertising

Sangamo Therapeutics, Inc

SGMOQ · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026